CD274 and small cell lung carcinoma: Secondly, considering the promising results of nivolumab plus chemotherapy as first-line treatment in SCLC patients in the EA5161 study and the accessibility and affordability of PD-L1 inhibitors in Chinese patients, 65% of the patients in this study were treated with PD-1 inhibitors, though only PD-L1 inhibitors have been approved as first-line treatment in SCLC patients by FDA.